59 patents
Utility
TGR5 modulators and methods of use thereof
7 Nov 23
Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
Filed: 14 Apr 22
Utility
Preparation and Uses of Obeticholic Acid
26 Oct 23
André STEINER, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
Filed: 22 Mar 23
Utility
Farnesoid X Receptor Modulators
27 Jul 23
Roberto PELLICCIARI
Filed: 3 Apr 23
Utility
Isotopically Labeled Bile Acid Derivatives
23 Feb 23
Gabriel GALVIN, Kevin SCHAAB, Matthew YANIK
Filed: 7 Sep 22
Utility
TGR5 Modulators and Methods of Use Thereof
1 Dec 22
Roberto PELLICCIARI, Antimo GIOIELLO, Antonio MACCHIARULO, Francoise PERRON-SIERRA, Klaus SEEDORF
Filed: 14 Apr 22
Utility
Isotopically labeled bile acid derivatives
18 Oct 22
Gabriel Galvin, Kevin Schaab, Mathew Yanik
Filed: 23 Jul 18
Utility
Pharmaceutical Compositions for Combination Therapy
8 Sep 22
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin).
Mark PRUZANSKI, Luciano ADORINI
Filed: 21 Mar 22
Utility
Pharmaceutical Compositions for Combination Therapy
8 Sep 22
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin).
Mark PRUZANSKI, Luciano ADORINI
Filed: 21 Mar 22
Utility
Medicine obtained by combining FXR agonist and ARB
23 Aug 22
The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof.
Tadashi Namisaki, Hitoshi Yoshiji
Filed: 27 Mar 17
Utility
Oral preparation of obeticholic acid
16 Aug 22
The present invention pertains to an oral preparation having exceptional elutability, the oral preparation containing obeticholic acid or a pharmacologically acceptable salt thereof, a water-soluble excipient, a disintegrating agent, and a water-soluble polymer binder, wherein the oral preparation is a quick-release tablet.
Mitsuhiro Matono, Tetsuya Hayama
Filed: 30 Mar 17
Utility
Pharmaceutical Compositions Comprising a FXR Agonist and a Fibrate for Use In the Treatment of Cholestatic Liver Disease
21 Jul 22
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and a fibrate.
Leigh A. MACCONELL, Richard PENCEK
Filed: 29 May 20
Utility
Methods of Using Obeticholic Acid
16 Jun 22
The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis.
Jeffrey EDWARDS, Sharon KARAN, Jason CAMPAGNA, Leigh A. MACCONELL
Filed: 23 Jul 21
Utility
TGR5 modulators and methods of use thereof
31 May 22
Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
Filed: 2 Sep 20
Utility
Film-coated tablet having high chemical stability of active ingredient
17 May 22
The present invention relates to a film-coated tablet having a high chemical stability of an active ingredient, said film-coated tablet comprising: (a) a tablet core containing obeticholic acid or a pharmaceutically acceptable salt thereof; and (b) a coating layer, which is provided on the surface of the tablet core, containing a film base and being substantially free from any plasticizer or containing at least one kind of specific plasticizer.
Mitsuhiro Matono, Tetsuya Hayama
Filed: 30 Mar 17
Utility
Compositions of Obeticholic Acid and Methods of Use
5 May 22
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Richard Gail LANCASTER, Kay K. OLMSTEAD, Masashi KAGIHIRO, Mitsuhiro MATONO, Ikuko TAOKA, Mark PRUZANSKI, David SHAPIRO, Roya HOOSHMAND-RAD, Richard PENCEK, Cathi SCIACCA, Lise ELIOT, Jeffrey EDWARDS, Leigh MACCONELL, Tonya MARMON
Filed: 6 Dec 21
Utility
3-desoxy derivative and pharmaceutical compositions thereof
3 May 22
Roberto Pellicciari, Antimo Gioiello
Filed: 18 Sep 20
Utility
Methods and Intermediates for the Preparation of Bile Acid Derivatives
28 Apr 22
Roberto PELLICCIARI, Antimo GIOIELLO, Gabriel GALVIN, Ronald D. LEWIS, II, Mathew YANIK, Myoung Goo KIM, Frederik Ronald LEUSINK, Bartjan KONING, Thomas HENSEL
Filed: 8 Jun 21
Utility
Pharmaceutical compositions for combination therapy
26 Apr 22
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin).
Mark Pruzanski, Luciano Adorini
Filed: 5 Feb 16
Utility
Treatment and Prevention of Intestinal Inflammatory Diseases with a Bile Acid Derivative
31 Mar 22
The present application relates to methods of treating or preventing an intestinal inflammatory disease or condition (e.g., intestinal ischemia reperfusion injury) in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the application.
Laurens CEULEMANS, Emilio CANOVAI
Filed: 3 Feb 20
Utility
Preparation and Uses of Obeticholic Acid
23 Dec 21
André STEINER, Heidi WAENERLUND POULSEN, Emilie JOLIBOIS, Melissa REWOLINSKI, Ralf GROSS, Emma SHARP, Fiona DUBAS-FISHER, Alex EBERLIN
Filed: 6 Jan 21